Blockchain Registration Transaction Record

Cybin Raises $175M in Direct Offering for Mental Health Breakthroughs

Cybin raises $175M in direct offering to advance psychedelic mental health treatments. Phase 3 trials for CYB003 in depression and Phase 2 for CYB004 in anxiety disorders.

This development represents a major vote of confidence in psychedelic medicine's potential to transform mental healthcare. With mental health disorders affecting hundreds of millions globally and traditional treatments often providing inadequate relief, Cybin's novel approaches could offer breakthrough solutions for conditions like major depressive disorder and anxiety. The substantial investment from reputable institutional backers validates the growing acceptance of psychedelic-assisted therapies in mainstream medicine. For patients struggling with treatment-resistant mental health conditions, this funding accelerates the development of potentially life-changing treatments that could provide lasting relief where current options have failed. The progress also signals a broader shift in how mental health is treated, moving beyond conventional pharmaceuticals toward more targeted, neuroplasticity-enhancing therapies.